Theratechnologies Wins ADRIQ's 2011 Product Innovation Award

Theratechnologies Wins ADRIQ's 2011 Product Innovation Award

ID: 90920

Tesamorelin Receives Praise as Innovative Product


(firmenpresse) - MONTREAL, CANADA -- (Marketwire) -- 11/24/11 -- Theratechnologies Inc. (TSX: TH)(NASDAQ: THER) was presented with the prestigious Product Innovation Award for its lead compound, tesamorelin, at the 21th Quebec Association of Industrial Research (ADRIQ) Innovation Awards Gala held on November 22, 2011.

"Theratechnologies is one of the few biotechs in Quebec that has managed to successfully gain FDA approval for a product and we are very proud to be recognized by ADRIQ," stated Mr. John-Michel T. Huss, President and Chief Executive Officer of Theratechnologies.

Tesamorelin, marketed in the U.S. as EGRIFTA® for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy, is a growth-hormone releasing factor discovered and developed by Theratechnologies in Quebec. It was approved in November 2010 by the U.S. Food and Drug Administration (FDA) and launched in the U.S. by a commercial partner in January 2011. Applications for tesamorelin are also currently under review with regulatory agencies in Canada, Europe, Latin America and the Middle East.

Founded in 1996, the Quebec Association of Industrial Research (ADRIQ) Product Innovation Award recognizes Quebec companies that have recently distinguished themselves by developing and marketing an innovative product, contributing to the company's growth in their respective markets.

About Theratechnologies

Theratechnologies (TSX: TH)(NASDAQ: THER) is a specialty pharmaceutical company that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at . Additional information, including the Annual Information Form and the Annual Report, is also available on SEDAR at and on the Securities and Exchange Commission's website at .



Contacts:
Serge Vallieres
NATIONAL Public Relations




514-843-2310

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  ProMetic Receives Confirmation of Octaplas(R)LG Regulatory Approval in Additional E.U. Countries RepliCel Class C Shareholders Convert Into Common Shares
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 24.11.2011 - 14:00 Uhr
Sprache: Deutsch
News-ID 90920
Anzahl Zeichen: 0

contact information:
Town:

MONTREAL, CANADA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 253 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Theratechnologies Wins ADRIQ's 2011 Product Innovation Award"
steht unter der journalistisch-redaktionellen Verantwortung von

Theratechnologies Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Theratechnologies Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z